ClinicalTrials.gg
CompletedNCT03340610ROTATEDUpdated May 24, 2019Results posted

IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab

A Phase 4 interventional study of Alflibercept in Diabetic Macular Edema, sponsored by Southeast Retina Center, Georgia. Completed at 1 site in United States. Open to participants aged 18 Years to 95 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-24.

Sponsored by Southeast Retina Center, Georgia · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Jun 2015, registered Nov 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.

Enrollment
38th of 53
30 · median 49
Started
2015
with 10 others
Phase 4
26 of 53
none open now
Registered
35th of 53
by date

Among the 53 studies testing aflibercept in Macular Edema, this one is the 38th largest by enrollment, is one of 11 that started in 2015, is one of 26 in phase 4, and was the 35th registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 95 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing aflibercept in Macular Edema, or all of them as a file.
02

Study summary

This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial. Study eyes will receive 5 required initial monthly Intravitreal Aflibercept (IAI) doses of 2 mg followed by 2q8 IAI for a total of 52 weeks; only one study eye from each patient will be enrolled.

Read the detailed description

This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial. Study eyes will receive 5 required initial monthly IAI doses of 2 mg followed by 2q8 IAI for a total of 52 weeks; only one study eye from each patient will be enrolled.

Starting at week 24, patients may be eligible to receive additional 2mg IAI (2q4) treatment if both of the following criteria is met and the investigator feels additional treatment would be beneficial:

  • Loss of >5 letters from baseline or best previously recorded best corrected visual acuity (BCVA)
  • Presence of new or recurrent intraretinal fluid or subretinal fluid as assessed by SD OCT

Starting at week 24, rescue therapy with macular laser photocoagulation may be administered if any the following criteria are met

  • Loss of > 15 letters from baseline or best previously recorded BCVA and loss of acuity felt to be secondary to Diabetic Macular Edema (DME) and not from other cause (i.e., cataract, epiretinal membrane, vitreous hemorrhage, etc) and investigator feels patient would benefit from rescue therapy
  • Increase in SD OCT CSF > 100 um from baseline or best previously recorded SD OCT CSF and investigator feels patient would benefit from rescue therapy.

Every 4 week visit will include ETDRS BCVA, IOP measurement, Slit lamp biomicroscopy, Indirect ophthalmoscopy, Heidelberg Spectralis SD-OCT and evaluation for systemic and ocular adverse events. Fundus Photography and Wide field Optos fluorescein angiography will be performed at baseline and at week 20and week 52.

STUDY DURATION: Approximately 52 weeks to the end of the study. Primary endpoint will be evaluated at week 52.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A patient must meet the following criteria to be eligible for inclusion in the study:

  1. Adults with Diabetes Mellitus 2. Documented history of ROTATE study completion (within 3 months +/- 1 week of exit visit) 3. BCVA ETDRS visual acuity letter score 20/25-20/400 4. Thickening due to DME involving the center of the macula evident on clinical exam 5. DME on OCT at baseline (>305 microns if male or >290 microns if female) as assessed on Heidelberg Spectralis SD OCT 6. At least 30 days but less than 45 days since prior 0.3 mg ranibizumab injection 7. Willing and able to comply with clinic visits and study-related procedures 8. Provide signed HIPAA statement and prior to any study procedures

Exclusion criteria

-

Exclusion Criteria:

A patient who meets any of the following criteria will be excluded from the study:

  1. Macular edema considered to be due to a cause other than DME (ERM, Vein Occlusion, Postop CME, uveitis)
  2. History of PRP within 3 months prior to enrollment or anticipated need for PRP
  3. History of idiopathic or uveitis in the study eye
  4. Cataract surgery in the study eye within 90 days of baseline
  5. Any intraocular surgery within 90 days of baseline
  6. Vitreomacular traction or epiretinal membrane in the study eye that is thought to affect vision
  7. pre-retinal fibrosis involving the macula in the study eye per investigator judgment
  8. Intraocular inflammation of trace or above in the study eye
  9. Evidence of active infection in either eye
  10. Uncontrolled glaucoma in the study eye defined as a pressure of > 25 on maximal medical therapy.
  11. Concurrent disease in the study eye, other than DME, that could compromise VA, require medical or surgical intervention during the study or could confound interpretation of the results
  12. Ocular media of insufficient quality to obtain fundus and OCT images
  13. Current treatment for a serious systemic infection
  14. Administration of systemic anti-angiogenic agents within 180 days of screen
  15. History of yag capsulotomy within 1 month prior to enrollment
  16. Receipt of any treatment for DME, other than ranibizumab 0.3 mg, in the study eye at any time in the past 3 months following ROTATE study exit, (such as focal/grid macular photocoagulation, intravitreal or peribulbar or other anti-VEGF agents such as Macugen, 2 mg IAI,, 0.5 mg ranibizumab, or intravitreal bevacizumab)
  17. Any women who are pregnant, breast-feeding, or attempting to become pregnant
  18. Sexually active men* or women of ** who are unwilling to practice adequate during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly)

    • Contraception is not required for men with documented vasectomy. ** women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Other
    Open Label Single Arm Trial

    Evaluating the efficacy of Alflibercept Injections in DME Following Treatment With Bevacizumab and Ranibizumab

    Drug: Alflibercept

Interventions

06

What researchers measure

Primary outcomes

  1. Reduction in Macular Edema

    Reduction in macular edema measured as * Proportion of eyes with baseline SD OCT CST \>350 um demonstrating \>15% reduction at week 52 from baseline * Proportion of eyes that demonstrate SD OCT CST \<305um (males) and \<290 um (females) at week 52 from baseline

    Time frame: 52 weeks from baseline

07

Results

Posted May 1, 2019
Limitations and caveats
Small sample size, no control group with continuation of bevacizumab/ranibizumab, 6 mth time point potentially skewed as last IAI at 4 mth due to protocol amendment. Loss of OCT, Fundus, Fluorescein Angiography on 1st 5 pts due to technical error

Participant flow

Participant flow — Overall Study
MilestonePhase 4 Prospective, Nonrandomized, Open Label, Interventional
Started30
Completed27
Not completed3

Outcome measures

PrimaryReduction in Macular Edema

Reduction in macular edema measured as * Proportion of eyes with baseline SD OCT CST \>350 um demonstrating \>15% reduction at week 52 from baseline * Proportion of eyes that demonstrate SD OCT CST \<305um (males) and \<290 um (females) at week 52 from baseline

Time frame:
52 weeks from baseline
Reported as:
Count of participants · Participants
Reduction in Macular Edema
ParticipantsOpen Label Single Arm Trial
OCT CST >350 um demonstrating >15% reduction15
OCT CST <305um (males)8
OCT CST<290 um (females)4

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 4 Prospective, Nonrandomized, Open Label, Interventional1/30 (3.3%)5/30 (16.7%)26/30 (86.7%)
Most frequent serious events
Most frequent serious events
EventPhase 4 Prospective, Nonrandomized, Open Label, Interventional
Hospitalization- Low electrolytesMetabolism and nutrition disorders1/30
DeathCardiac disorders1/30
CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30
SepsisInfections and infestations1/30
Kidney FailureRenal and urinary disorders1/30
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPhase 4 Prospective, Nonrandomized, Open Label, Interventional
Common ColdInfections and infestations9/30
Kidney/Liver ConditionsRenal and urinary disorders6/30
HerniaGastrointestinal disorders3/30
CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/30
Subconjunctival HemorrhageEye disorders2/30
Cardiovascular eventsCardiac disorders1/30
Bladder InfectionInfections and infestations1/30
BlepharitisInfections and infestations1/30
Cataract ExtractionSurgical and medical procedures1/30
Yag Laser CapsulotomySurgical and medical procedures1/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Open Label Single Arm Trial
<=18 years0
Between 18 and 65 years15
>=65 years15
Age, Continuous
Age, Continuous(years)Open Label Single Arm Trial
Mean63 (43 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Open Label Single Arm Trial
Female13
Male17
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Open Label Single Arm Trial
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American15
White15
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Open Label Single Arm Trial
United States30
Insulin Dependency (Independent/Dependent)
Insulin Dependency (Independent/Dependent)(Participants)Open Label Single Arm Trial
Independent13
Dependent17
Diabetic Retinopathy (Proliferative/Non-Proliferative)
Diabetic Retinopathy (Proliferative/Non-Proliferative)(Participants)Open Label Single Arm Trial
Proliferative11
Non-Proliferative19
Average Anti-VEGF Injections Received Prior to Baseline
Average Anti-VEGF Injections Received Prior to Baseline(injections)Open Label Single Arm Trial
Mean14.5 (6 to 48)

4 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Southeast Retina Center
    Augusta, Georgia 30809, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Dec 2018, 42 months.

Results were first posted in May 2019, 5 months after primary completion.

Of 51 non-industry phase 4 interventional studies under Macular Edema, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's 42 months is above that.

Counting every sponsor, half of 63 studies reached it within 26 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2017
First posted
Nov 13, 2017
StartActual
Jun 2015
Primary completionActual
Dec 2018
CompletionActual
Dec 12, 2018
Results first posted
May 1, 2019
Last update
May 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03340610
Lead sponsor
Southeast Retina Center, Georgia
Responsible party
Sponsor
First posted
Nov 13, 2017
Start date
Jun 2015
Primary completion
Dec 2018
Completion
Dec 12, 2018
Results posted
May 1, 2019
Last update
May 24, 2019

Study contacts

Dennis M Marcus, MD
principal investigator · Southeast Retina Center, PC.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion